Jiangsu Nhwa Pharmaceutical Co., LTD

002262

CNE100000CG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
23.17 ^CNY	-1.32%		-4.06%	-14.56%

05-24	Nhwa Pharma Gets China Nod to Register Epilepsy Drug	MT
04-19	Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Jiangsu Nhwa Pharmaceutical Co., LTD Elects Board of Directors

April 01, 2019 at 04:36 pm

Jiangsu Nhwa Pharmaceutical Co., LTD held its Annual General Meeting of 2018 on 29 March 2019, during which, Wu Yonghe, Kong Xusheng and Zhang Lei elected as independent directors, Wang Fengshou and Jia Xinglei elected as non-employee supervisors.

Latest news about Jiangsu Nhwa Pharmaceutical Co., LTD

Nhwa Pharma Gets China Nod to Register Epilepsy Drug	05-24	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets	04-03	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week	02-26	MT
Teva Pharmaceutical Investments Singapore Pte Ltd. and Jiangsu Nhwa Pharmaceutical Co., LTD Forge Strategic Partnership to Promote Patient Access to Austedo® in China	02-26	CI
Nhwa Pharmaceutical Gets Green Light from US FDA After Addressing API Deficiencies	12-21	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Beijing Yihua M-Health Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Jiangsu Nhwa Pharmaceutical Co., LTD	24/10/23	CI
Jiangsu Nhwa Pharmaceutical Co., LTD(XSEC:002262) added to FTSE All-World Index	18/09/23	CI
Jiangsu Nhwa Pharma’s H1 Profit Jumps 21.7% as Revenue Rises 20%	31/07/23	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	30/07/23	CI
Wang Zeyu cancelled the acquisition of 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD.	27/07/23	CI
Expected House Vote on Debt Ceiling Deal Weighs on Sentiment, Pushing US Equity Futures Lower	31/05/23	MT
Trevena Receives $3 Million Milestone Payment From Partner Jiangsu Nhwa Pharmaceutical	31/05/23	MT
Top Premarket Gainers	31/05/23	MT
Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK	08/05/23	CI
Jiangsu Nhwa Pharma’s Q1 Profit Jumps 20.5% as Revenue Rises 19%; Shares Jump 5%	14/04/23	MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2023	13/04/23	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Mr Wang Zeyu agreed to acquire 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD for CNY11.4673 million.	29/07/22	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2022	29/07/22	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors	05/05/22	CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2022	22/04/22	CI
Trevena Secures First $15 Million Tranche from Royalty-Based Financing with R-Bridge Healthcare Fund	18/04/22	MT

Chart Jiangsu Nhwa Pharmaceutical Co., LTD

Duration

Period

Chart Jiangsu Nhwa Pharmaceutical Co., LTD

More charts

Company Profile

Jiangsu Nhwa Pharmaceutical Co., LTD is a China-based company principally engaged in the production and sales of pharmaceutical preparations. The Company offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The Company is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Jiangsu Nhwa Pharmaceutical Co., LTD

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.17 CNY

Average target price

32.21 CNY

Spread / Average Target

+39.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANGSU NHWA PHARMACEUTICAL CO., LTD	-14.56%	3.22B
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals